In this randomized, double-blind Phase 2 trial of 205 Chinese patients, UBT251 achieved up to 19.7% mean weight loss at 24 weeks from a baseline mean weight of 92.2 kg, compared to 2.0% with placebo. How should we interpret this magnitude of weight loss at the 24-week mark relative to what we typically expect from GLP-1–based therapies at similar timepoints?

The study evaluated once-weekly 2 mg, 4 mg, and 6 mg doses. From a clinical development perspective, what would you want to understand about the dose-response gradient—particularly in balancing incremental efficacy against gastrointestinal tolerability?

UBT251 targets GLP-1, GIP, and glucagon receptors simultaneously. How might the addition of glucagon receptor agonism contribute metabolically to the observed weight reduction, and what theoretical advantages—or risks—does this mechanism introduce compared to dual agonists?

All dose groups demonstrated statistically significant improvements versus placebo across key secondary endpoints, including waist circumference, blood glucose, blood pressure, and lipids. How important is this broad cardiometabolic signal when evaluating obesity drugs as long-term risk-modifying therapies rather than purely weight-loss agents?

This study enrolled Chinese patients with BMI thresholds adjusted for Asian populations (≥28 kg/m² for obesity, ≥24 kg/m² with comorbidity). Are there physiological or metabolic differences in Asian populations that could influence responsiveness to incretin-based triple agonists?

The safety profile was described as consistent with incretin-based therapies, with mostly mild-to-moderate gastrointestinal adverse events that diminished over time. In your view, what level of GI burden is acceptable in exchange for nearly 20% weight loss at 24 weeks?

United Biotechnology plans to initiate a Phase 3 trial in Chinese patients, while Novo Nordisk has launched a global Phase 1b/2a study. What key design elements—duration, comparator choice, cardiovascular endpoints, or durability of effect—will be critical to validate these Phase 2 findings?

With Novo Nordisk also planning a Phase 2 trial in type 2 diabetes in the second half of 2026, how might UBT251 ultimately be positioned—pure obesity, obesity plus diabetes, or as a broader metabolic therapy—and what would determine whether it differentiates meaningfully in an increasingly crowded incretin market?